Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene cause late-onset, autosomal dominant Parkinson's disease (PD). LRRK2 mutations typically give rise to Lewy pathology in the brains of PD subjects yet can induce tau-positive neuropathology in some cases. The pathological interaction between LRRK2 and tau remains poorly defined. To explore this interaction in vivo, we crossed a well-characterized human P301S-tau transgenic mouse model of tauopathy with human G2019S-LRRK2 transgenic mice or LRRK2 knockout (KO) mice. We find that endogenous or pathogenic LRRK2 expression has minimal effects on the steady-state levels, solubility and abnormal phosphorylation of human P301S-tau throughout the mouse brain. We next developed a new model of tauopathy by delivering AAV2/6 vectors expressing human P301S-tau to the hippocampal CA1 region of G2019S-LRRK2 transgenic or LRRK2 KO mice. P301S-tau expression induces hippocampal tau pathology and marked degeneration of CA1 pyramidal neurons in mice, however, this occurs independently of endogenous or pathogenic LRRK2 expression. We further developed new AAV2/6 vectors co-expressing human WT-tau and GFP to monitor the neuronto-neuron transmission of tau within defined hippocampal neuronal circuits. While endogenous LRRK2 is not required for tau transmission, we find that G2019S-LRRK2 markedly enhances the neuron-to-neuron transmission of tau in mice. Our data suggest that mutant tau-induced neuropathology occurs independently of LRRK2 expression in two mouse models of tauopathy but identifies a novel pathogenic role for G2019S-LRRK2 in promoting the neuronal transmission of WT-tau protein. These findings may have important implications for understanding the development of tau neuropathology in LRRK2-linked PD brains.
Introduction
Mutations in the leucine-rich repeat kinase 2 (LRRK2, PARK8) gene are the most common known cause of familial Parkinson's disease (PD) with autosomal dominant inheritance (1) (2) (3) . LRRK2 is a large multi-domain protein that contains a serine/threoninedirected protein kinase domain, a small GTPase domain and several repeat domains (4) . The most frequent LRRK2 mutation, G2019S, is located within the kinase activation loop and accounts for 5-6% of familial and 1-2% of idiopathic PD cases (1, 5) . LRRK2-linked PD subjects display clinical features that are largely indistinguishable from idiopathic PD and similar neuropathological features (5, 6) . The majority of brains with LRRK2 mutations display dopaminergic neuronal loss in the substantia nigra accompanied by typical brainstem Lewy pathology (3, 5, 7, 8) . However, a small proportion of LRRK2-linked brains exhibit heterogeneous neuropathology, including diffuse Lewy pathology, ubiquitin-positive inclusions, tau-positive neurofibrillary tangle pathology, TDP-43-positive inclusions or the absence of protein pathology (3, 5, (9) (10) (11) (12) .
The significance of tau pathology for LRRK2-linked or idiopathic PD is poorly understood. Common variation at or near the LRRK2 and MAPT (encoding tau) genomic loci is associated with an increased risk of developing idiopathic PD (13) (14) (15) . Furthermore, mutations in the MAPT gene cause frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) (16), whereas tau-positive pathology is the hallmark of numerous neurodegenerative dementias and movement disorders collectively termed tauopathies (17) . LRRK2 pathogenic mutations have also been identified in subjects with tauopathy, including progressive supranuclear palsy and corticobasal degeneration (18) . The formation of tau-positive neurofibrillary tangles (NFTs) is the major pathological feature of neurodegenerative tauopathies (17, 19) . NFTs contain paired helical filaments of tau that are abnormally hyperphosphorylated (19) . Tau protein function is normally regulated by phosphorylation that can vary throughout development (20) . However, in many tauopathies, tau becomes hyperphosphorylated with >60 disease-associated phosphorylation sites identified. Several protein kinases and phosphatases are implicated in regulating tau phosphorylation, for example GSK3b and cdk5 (20) . Intriguingly, recent studies suggest that LRRK2 can also directly phosphorylate tau protein in vitro or in cultured cells (21, 22) , or LRRK2 may indirectly facilitate tau phosphorylation by regulating tau kinases, such as GSK3b or cdk5 (23) (24) (25) (26) .
In vivo studies exploring the interaction of LRRK2 and tau have so far reported contrasting findings. BAC transgenic mouse models expressing R1441G or G2019S LRRK2 exhibit either tau hyperphosphorylation or altered tau metabolism in the brain, respectively (27) (28) (29) . In rats, the adenoviral vector-mediated expression of human LRRK2 variants in the nigrostriatal dopaminergic pathway leads to a transient increase in tau phosphorylation (AT8-positive) (30) . These data suggest that disease-linked LRRK2 mutations can induce modest alterations in endogenous tau protein in the rodent brain. Two recent studies have further addressed the effects of LRRK2 on neuropathology induced by FTDP-17-linked mutant human tau in wellestablished transgenic models of tauopathy. In one study, BAC mice expressing human WT LRRK2 were crossed to inducible P301L-tau transgenic mice (rTg4510) (21) . WT LRRK2 expression increased the levels of sarkosyl-insoluble human tau and its phosphorylation at known or novel epitopes (T149, pT205 and AT8) in whole brain extracts (21) . In contrast, a second study using BAC mice expressing human R1441G LRRK2 crossed with prion protein promoter (PrP)-driven human P301S-tau transgenic mice, demonstrated no effect of R1441G LRRK2 expression on tau pathology, disease-onset, premature survival and neuronal loss in the P301S-tau mice (31) .
At this juncture, the contribution of LRRK2 to the development of tau neuropathology remains uncertain. Importantly, the contribution of the most frequent G2019S mutation in LRRK2 or the role of endogenous LRRK2 in the development of tau pathology has not yet been addressed. In the present study, we employ two distinct mouse models of tauopathy combined with human G2019S LRRK2 transgenic or LRRK2 knockout mice to comprehensively evaluate the impact of LRRK2 on the development of tau pathology, neuron-to-neuron transmission and neurodegeneration. Our data suggest that tau neuropathology occurs largely independently of LRRK2 expression but reveals an intriguing pathogenic role for G2019S LRRK2 in enhancing the neuronal transmission of human tau protein.
Results

Generation of P301S-tau/LRRK2 knockout and P301S-tau/G2019S-LRRK2 mice
To initially evaluate the potential interaction of LRRK2 and tau in vivo, mice were generated to overexpress human P301S tau either on a LRRK2 knockout (KO) background or together with transgenic overexpression of human G2019S LRRK2 (Fig. 1) . We developed crossbreeding strategies of existing genetically modified mouse models similar to our previous study (32) . Homozygous LRRK2 KO mice with a targeted deletion of exon 41 (33) were bred to hemizygous P301S-Tau transgenic mice (human 4R1N isoform) driven by the mouse prion protein promoter (line PS19) (34) (Fig. 1A) . To minimize potential strain effects, LRRK2 heterozygous mice (LRRK2 þ/À ) were bred to double heterozygous mice (P301S-Tau/LRRK2
þ/À ) generated in the first round of breeding. We generated cohorts of age-matched littermate mice consisting of i) wild-type (WT), ii) LRRK2
) genotypes at the expected Mendelian ratios for further analysis (Fig. 1A) . In addition, transgenic mice expressing human G2019S LRRK2 from a CMV-enhanced PDGFb promoter (line 340) (35) were bred to P301S-Tau transgenic mice. We crossed hemizygous G2019S-LRRK2 mice with hemizygous P301S-Tau mice to produce cohorts of age-matched littermates consisting of i) WT nontransgenic (non-Tg), ii) G2019S-LRRK2 Tg (LRRK2
G2019S
), iii) P301S- Tau   Tg   (Tau   P301S   ) and iv) G2019S-LRRK2 Tg /P301S- Tau   Tg   (LRRK2   G2019S   /Tau   P301S ) genotypes at expected ratios (Fig. 1B) . P301S-Tau mice develop a robust progressive and lethal neurodegenerative tauopathy with the onset of neurofibrillary pathology in multiple brain regions at $5 months, synaptic loss and neuronal degeneration from 6-12 months, motoric deficits and limb paralysis, leading to premature death by $12 months (34).
In the mouse brain, endogenous LRRK2 protein is localized to neurons throughout the forebrain and midbrain regions, with highest levels in the cerebral cortex, hippocampus and striatum but also in the substantia nigra (35) (36) (37) (38) . G2019S LRRK2 is broadly expressed throughout the brain of PDGFb-LRRK2 transgenic mice with highest expression in the olfactory bulb, cerebral cortex, hippocampus, striatum and cerebellum (35) . Human P301S-Tau is expressed throughout the brain of PS19 transgenic mice with tau-positive neurofibrillary pathology detected in the cortex, hippocampus, amygdala, brainstem and spinal cord starting from $5 months of age (34) . Therefore, endogenous or transgenic LRRK2 and transgenic tau are known to be present in a number of similar neuronal populations and brain regions within the mouse brain where they may pathologically interact. To provide a comprehensive evaluation of the potential interaction between LRRK2 and tau proteins throughout the mouse brain, cohorts of mice were assessed prior to symptom onset at 6 months of age to evaluate early and potentially subtle alterations in the onset and extent of tau pathology due to modulating LRRK2 expression. Mouse hemi-brains were dissected into six anatomic regions (cortex, striatum, ventral midbrain, brainstem, cerebellum and spinal cord) for biochemical analysis and the remaining hemi-brain was formalin-fixed for immunohistochemical analysis. In general, LRRK2 deletion or G2019S LRRK2 overexpression does not alter the survival or gross phenotype of P301S-Tau mice up to 6 months of age with no early lethality or symptom onset occurring in these mouse cohorts over this period.
LRRK2 deletion or overexpression fails to alter tau levels, solubility and abnormal phosphorylation in P301S-tau transgenic mice
To determine whether endogenous or pathogenic LRRK2 impacts the development of tau pathology, we sought to determine whether LRRK2 deletion or human G2019S-LRRK2 overexpression would alter the steady-state levels, solubility or abnormal phosphorylation of human P301S-Tau in the mouse brain. Brain tissues were subjected to sequential detergent extraction with buffers of increasing strength using low salt, 1% Triton-X100 and 1% sarkosyl buffers, respectively. Western blot analysis was first conducted for each genotype to compare total human tau levels and solubility (using a human-specific tau E1 antibody; residues 19-33) across each mouse brain region and fraction. Human P301S-Tau protein migrates as a $55 kDa species and is abundantly detected in each brain region, and in the low salt, Triton-X100 and sarkosyl-soluble fractions, but to a much lesser extent in the sarkosyl-insoluble fraction (Fig. 2 , Supplementary Material, Figs S1 and S2). Densitometric analysis reveals only minimal differences in total tau levels in each soluble brain fraction between LRRK2-WT/Tau and LRRK2-KO/Tau littermate mice ( Fig. 2C and Supplementary Material, Fig. S1 ), or between G2019S-LRRK2/Tau and non-Tg/Tau littermate mice ( Fig. 2D and Supplementary Material, Fig. S2 ). LRRK2 deletion results in a modest yet significant reduction of tau in the Triton X100-soluble fraction from cortex and cerebellum but is increased in the sarkosyl-soluble fraction from striatum ( Fig. 2 and Supplementary Material, Fig. S1 ). Tau is significantly increased in the Triton X100-soluble fraction from spinal cord due to G2019S LRRK2 expression ( Fig. 2 and Supplementary Material, Fig. S2 ). In general, however, modulating LRRK2 expression does not robustly or consistently alter the steadystate levels or solubility of human P301S-Tau throughout the mouse brain. It was not possible to quantify tau levels in the sarkosyl-insoluble fraction due to the absence of a reliable protein loading control, however, there are no qualitative alterations of tau in this fraction between LRRK2 genotypes (Supplementary Material, Figs S1 and S2). The modest accumulation of tau in the sarkosyl-insoluble fraction of P301S-Tau transgenic mice at 6 months is consistent with the early development of neurofibrillary pathology reported in this model (34) . We also evaluated whether modulating LRRK2 expression could alter the proteolytic processing of human tau in the brain by using a human-specific tau antibody directed to the C-terminal region (Tau46; residues 404-441). While we could readily detect truncated species of tau of !25 kDa consistent with removal of the N-terminal region, we do not observe an obvious effect of LRRK2 deletion (Supplementary Material, Fig. S3A ) or G2019S-LRRK2 overexpression (Supplementary Material, Fig. S3B ) on the level of truncated tau species or on tau processing in general in the sarkosyl-soluble fraction of each brain region.
We next sought to determine whether modulating LRRK2 expression influences the abnormal phosphorylation of human P301S-Tau in the mouse brain. Tau hyperphosphorylation is a key feature of neurofibrillary pathology in neurodegenerative tauopathies (17, 20) , as well as in the P301S-Tau transgenic mice (34) . LRRK2 has previously been reported to phosphorylate tau in vitro, as well as to promote the abnormal phosphorylation of human tau in the brains of P301L-Tau transgenic mice (21) . Western blot analysis was conducted on sequential detergent fractions of each brain region using well-characterized phosphorylation-specific tau antibodies recognizing pSer202/ pThr205 (AT8), pSer202 (CP13) and pSer396/pSer404 (PHF1). Tau phosphorylation could be abundantly detected in the low salt and Triton X100-soluble fractions of the cortex, brainstem, striatum and ventral midbrain of mice ( Fig. 3 and Supplementary Material, Fig. S4 ), but not reliably detected in the sarkosylsoluble and sarkosyl-insoluble brain fractions at this age (data not shown). Densitometry reveals only minimal differences in tau phosphorylation between LRRK2-WT/Tau and LRRK2-KO/ Tau littermate mice (Fig. 3) , or between G2019S-LRRK2/Tau and non-Tg/Tau littermate mice (Fig. 3) . Surprisingly, LRRK2 deletion results in a significant increase of tau phosphorylation (CP13 and PHF1) in the Triton X100-soluble fraction of cortex but not in other brain regions ( Fig. 3C and Supplementary Material, Fig. S4 ). G2019S LRRK2 expression fails to significantly alter tau phosphorylation in these brain regions and fractions although a non-significant trend of increased phospho-tau (AT8) in the low salt fraction from cortex is observed (Fig. 3A-B) . In general, however, modulating LRRK2 expression does not robustly alter the abnormal phosphorylation of human P301S-Tau throughout the mouse brain. To confirm the accumulation of hyperphosphorylated tau and neurofibrillary pathology in the P301S-Tau mice at 6 months of age, sagittal hemi-brain sections for each mouse genotype were subjected to immunohistochemistry for human tau (E1 antibody) or phosphorylated tau (AT8, PHF1 and CP13 antibodies). We could confirm the equivalent levels and distribution of human tau as well as early neurofibrillary pathology containing hyperphosphorylated tau in the cortex, hippocampus and spinal cord of P301S-Tau mice that is not qualitatively altered by LRRK2 KO or G2019S LRRK2 overexpression (Supplementary Material, Fig. S5 ). The small extent of neurofibrillary pathology in these mice at 6 months is consistent with the low levels of human tau detected in the sarkosyl-insoluble fraction (Supplementary Material, Figs S1 and S2). Collectively, our data suggest that endogenous or pathogenic LRRK2 expression does not influence the steady-state levels, solubility, processing or abnormal phosphorylation of human P301S-Tau protein in the brain of pre-symptomatic transgenic mice. Importantly, our data fail to provide evidence that human G2019S LRRK2 expression can exacerbate abnormal tau phosphorylation and the development of neurofibrillary pathology, consistent with a similar study crossing R1441G-LRRK2 and P301S-Tau transgenic mice (31) .
LRRK2 fails to interact with and phosphorylate human tau
Our data from mouse cross-breeding studies strongly suggest that LRRK2 expression does not influence the onset and development of tauopathy in a well-established tau transgenic mouse model. While our data is consistent with a recent prior study (31) , it disagrees with another study suggesting that human LRRK2 promotes the phosphorylation of tau in vitro and in vivo (21) . To further extend our observations from mice, we first sought to determine whether human LRRK2 can interact with human tau in mammalian cells. HEK-293T cells transiently co-expressing combinations of FLAG-tagged human LRRK2 (WT or PD mutants, R1441C, Y1699C, G2019S) and Myc-tagged human tau (WT or P301L; 4R0N isoform) were subjected to co-immunoprecipitation with either anti-Myc antibody WT and P301L tau fail to specifically interact with LRRK2 variants in these assays. Next, we sought to determine whether LRRK2 is capable of phosphorylating tau in vitro using radioactive kinase assays, as previously reported (21) . We combined recombinant GST-tagged human LRRK2 variants (residues 970-2527; WT, G2019S or kinase-inactive D1994A) together with recombinant human WT tau (residues 1-441, 4R2N) and [ 33 P]-c-ATP. GST-tagged ArfGAP1, a well-characterized LRRK2 substrate (39), served as a positive control. WT and G2019S LRRK2 fail to specifically phosphorylate tau in these assays compared with kinase-inactive D1994A LRRK2 whereas we are able to detect robust LRRK2 autophosphorylation and LRRK2-mediated phosphorylation of ArfGAP1 (Supplementary Material, Fig. S6C ). Our data finds no evidence for robust LRRK2-mediated tau phosphorylation in vitro, in contrast to a prior study (21) .
AAV2/6-Tau
P301S induces hippocampal tauopathy and neuronal loss in mice: impact of endogenous or pathogenic LRRK2
To further explore the relationship between LRRK2 and tau, we sought to explore their interaction in a more rapid and selective mouse model that develops tau pathology and neuronal loss restricted to a focused brain region. We elected to focus on the hippocampus as endogenous (and transgenic) LRRK2 is abundantly distributed to most neuronal populations within this region (35) (36) (37) . Furthermore, hippocampal neurons selectively develop tau pathology in a number of neurodegenerative tauopathies (17) . We reasoned therefore that LRRK2 and tau are highly likely to directly encounter each other in vulnerable neurons in such a model compared with our mouse crossbreeding studies where LRRK2 and tau proteins may not always colocalize. Furthermore, the low burden of tau pathology occurring in the pre-symptomatic P301S-Tau mice represents a limiting factor for assessing the impact of LRRK2 on the development of tauopathy in this model. To address these issues, we developed a viral-mediated gene transfer mouse model of mutant tau-induced neuropathology and neurodegeneration. Recombinant adeno-associated viral (AAV2/6) vectors expressing human P301S-Tau (4R0N) from a constitutive PGK1 promoter were developed and delivered by stereotactic surgery to the ipsilateral CA1 region of the mouse hippocampus. An empty control virus lacking tau (AAV2/6-MCS) was similarly delivered to mice in parallel. To evaluate the role of endogenous LRRK2 versus pathogenic LRRK2 on tau-induced neurodegeneration, distinct cohorts of LRRK2 KO mice or G2019S-LRRK2 transgenic mice were generated together with their corresponding WT or non-transgenic littermate controls. Mice at 5-6 months of age were subjected to unilateral hippocampal injections of AAV2/6 vectors and sacrificed for perfusion-fixation at 8 weeks post-injection for immunohistochemical analyses. Using a human-specific tau antibody (E1), we find human P301S-Tau to be broadly and equivalently distributed to neurons throughout the ipsilateral hippocampus and adjacent cerebral cortex of LRRK2 KO, G2019S-LRRK2 and littermate control mice. P301S-Tau is abundantly detected in all layers of the hippocampal CA1-CA3 region including the pyramidal cell layer, stratum radiatum and stratum lacunosum/molecular as well as cortical layers I-VI within the ipsilateral hemisphere (Fig. 4) . Intriguingly, P301S-Tau is also detected although to a lesser extent in the CA1-CA3 and cortical regions of the contralateral hemisphere most likely due to the interconnectivity of these regions between opposite hemispheres (Fig. 4) . Human tau immunoreactivity is absent from the hippocampus following injection with a control virus (AAV-MCS) as expected (Fig. 4) . To evaluate the impact of LRRK2 on the development of tau pathology in mice injected with AAV-Tau P301S vector, immunohistochemistry was conducted using antibodies to abnormally phosphorylated (AT8 and PHF1) or conformation-specific (MC1, pre-PHF conformation) tau epitopes. Within the ipsilateral hemisphere, we observe the accumulation of tau-positive neuropathology localized to neurites, neuropil and neuronal soma in the CA1-CA3 and cortical regions in AAV-Tau P301S -injected mice compared with AAV-MCS-injected mice (Fig. 5 ). This tau pathology corresponds well with the pattern of total human P301S-Tau protein detected with the Tau/E1 antibody in these regions (Fig. 5) . Importantly, the extent of tau pathology is qualitatively similar in levels, distribution and morphology between LRRK2 KO and WT mice or between G2019S-LRRK2 transgenic and non-transgenic mice (Fig. 5 ). Our data suggest that endogenous LRRK2 or overexpression of pathogenic G2019S-LRRK2 does not robustly influence the extent of tau neuropathology induced by AAV-Tau P301S in the mouse hippocampus.
To further explore the impact of LRRK2 on tau-related pathology in this AAV model we sought to determine whether human P301S-Tau expression induces neurodegeneration in the hippocampus coincident with tauopathy. Immunohistochemistry was conducted for the neuronalspecific marker NeuN to evaluate the loss of pyramidal neurons in the CA1-CA3 region. AAV-Tau P301S induces a marked and specific loss of pyramidal neurons in the ipsilateral CA1 region compared with the intact contralateral CA1 region (Fig. 6 ). AAV-MCS does not similarly result in a loss of CA1 neurons thereby confirming the specific pathological effects of P301S-Tau (Fig. 6 ). Unbiased stereological analysis of NeuN-positive pyramidal neurons in the CA1 region reveals a marked neuronal loss in the ipsilateral CA1 compared with the contralateral CA1 due to AAV-Tau P301S in WT mice (36.7 6 8.2% loss), with no difference observed in LRRK2 KO mice (36.5 6 6.9% loss) (Fig. 6 ). AAVTau P301S induces a non-significant increase in neuronal loss in the ipsilateral CA1 in G2019S-LRRK2 mice (46.0 6 9.2% loss) compared with their non-transgenic littermates (32.2 6 9.3% loss) (Fig. 6 ). Taken together, these data demonstrate that endogenous or pathogenic LRRK2 expression does not robustly alter hippocampal neurodegeneration induced by human P301S-Tau.
G2019S-LRRK2 overexpression promotes the hippocampal neuron-to-neuron transmission of human tau
Tau has been shown to possess prion-like properties and neuronal spreading of tau is considered to play a key role in the development of tau pathology and neurodegeneration (40) (41) (42) . Several paradigms have been developed to study the neuron-toneuron transmission of tau in vivo (40, 43) . However, the role of LRRK2 in tau transmission is poorly studied. To explore a potential role, we developed a viral-mediated gene transfer model using AAV2/6 vectors that co-express human WT-Tau (4R0N) and nuclear-localized eGFP from the same PGK1 promoter (Supplementary Material, Fig. S7A ). Using this vector, we observe the trans-synaptic transfer of human WT-Tau from ipsilateral CA1 neurons at the injection site to ipsilateral CA3 neurons and contralateral CA3 neurons via the commissural pathway (Fig. 7A) . Whereas tau can transfer from neuron to neuron, co-expressed eGFP in this AAV2/6 vector reveals a limited capacity to transfer to connected CA3 neurons and therefore serves as a control for monitoring trans-synaptic viral transport and transduction (Fig. 7A) . Immunofluorescence colabeling using antibodies specific for human tau (clone E1) and GFP was employed to detect the expression of human WT-Tau and eGFP. Our data reveal the abundant presence of GFP þ /Tau þ neurons in the ipsilateral CA1 region (Fig. 7B-C) and to a lesser extent the ipsilateral CA3 region (Fig. 7E) , whereas GFP -/Tau þ neurons are readily detected in the contralateral CA3 region (Fig. 7D-E) . To explore the impact of LRRK2 expression on neuronal tau transmission throughout the hippocampus, AAV2/6-Tau WT /eGFP nls vectors were delivered unilaterally to the CA1 region of LRRK2 KO and G2019S-LRRK2 transgenic mice and their WT or non-transgenic littermate controls and brain tissue was collected at 8 weeks post-injection (Fig. 8A) . As expected, the prominent co-expression of GFP and WT-Tau is detected in neurons (GFP þ /Tau þ ) of the ipsilateral CA1 region of each mouse genotype (Fig. 8A) . In contrast to P301S-Tau expression (Fig. 6) , we do not observe obvious neuronal loss in the ipsilateral CA1 region following human WT-Tau expression as indicated by equivalent nuclear staining (DAPI) or NeuN immunostaining in this region (Supplementary Material, Fig. S7B and C) . Furthermore, WT-Tau expression does not produce tau pathology as indicated by the lack of abnormal tau phosphorylation (AT8, PHF1 or CP13) in the ipsilateral CA1 and cortical regions (Supplementary Material, Fig. S7D-F) . Surprisingly, we detect a small proportion of neurons expressing only WT-Tau (GFP -/ Tau þ ) in the CA1 (Figs 7 and 8A ). We speculate that human tau transfers between neighboring neurons in this region. Importantly, we consistently detect GFP -/Tau þ neurons in the ipsilateral and contralateral CA3 regions of each mouse genotype, indicating the efficient transmission of WT-Tau from CA1 to CA3 neurons in this model (Fig. 8A) . Occasionally, GFP þ /Tau þ neurons are detected in the ipsilateral and contralateral CA3 regions suggesting a limited movement of the AAV vector from the CA1 region to connected neurons (Fig. 8A ). Using this tau neuron-to-neuron transmission paradigm, we find that the neuronal transfer of WT-Tau occurs independently of endogenous LRRK2 expression with LRRK2 KO and WT mice revealing a similar number of GFP -/Tau þ neurons in the ipsilateral and contralateral CA3 regions (Fig. 8B) . Intriguingly, G2019S-LRRK2 transgenic mice reveal a significant $2-fold increase of GFP -/ Tau þ neurons in both CA3 regions compared with their nontransgenic littermates (Fig. 8C ). Our data suggest that endogenous LRRK2 is dispensable for the neuronal transmission of tau in the mouse hippocampus whereas pathogenic LRRK2 promotes the neuron-to-neuron transfer of tau.
Discussion
Here, we have comprehensively evaluated the effects of endogenous and pathogenic LRRK2 expression on the development of tau neuropathology and tau neuronal transmission in two complementary mouse models. First, we generated bigenic models by crossing transgenic mice expressing human P301S-tau with either LRRK2 KO mice or human G2019S-LRRK2 transgenic mice. We demonstrate that endogenous or pathogenic LRRK2 expression has minimal effects on the steady-state levels, solubility or abnormal phosphorylation of human tau protein throughout the mouse brain. Second, we delivered adeno-associated viral vectors expressing human P301S-tau to the hippocampus of LRRK2 KO or G2019S-LRRK2 transgenic mice. Similar to the studies with bigenic mice, we find that endogenous LRRK2 is not required for P301S-tau-induced neuropathology and neurodegeneration. Furthermore, we demonstrate that G2019S-LRRK2 expression does not exacerbate tau-related neuropathology in this mouse model of tauopathy. Third, we employed AAV vectors expressing human WT-tau to demonstrate that endogenous LRRK2 does not play a role in the neuron-to-neuron transmission of tau protein in the hippocampus. Intriguingly, however, we find that G2019S-LRRK2 enhances the neuronal transmission of tau. Taken together, our data suggest a limited CA1-CA3 and dentate gyrus (DG) regions are indicated. Unbiased stereological counting of NeuN-positive neurons in the ipsilateral and contralateral CA1 regions (contoured area) does not reveal significant differences in P301S-tau-induced neuronal loss between LRRK2-KO and LRRK2-WT mice, or between G2019S-LRRK2 transgenic and non-transgenic mice. Graphs indicate the loss of NeuN-positive neurons in the ipsilateral CA1 as a percent of the intact contralateral CA1 for each mouse genotype following AAV-P301S-tau delivery (n ¼ 3 mice/genotype; mean 6 SEM). P > 0.05 by two-tailed, unpaired Student's t-test.
role for endogenous or pathogenic LRRK2 in the development of mutant tau-induced neuropathology in two distinct mouse models of tauopathy, although pathogenic LRRK2 can promote the neuron-to-neuron transmission of WT tau protein.
To initially explore the interaction between LRRK2 and tau in vivo, we have crossed a well-characterized mouse model that develops a lethal neurodegenerative tauopathy, human P301S-tau transgenic mice, with LRRK2 KO mice or human G2019S-LRRK2 transgenic mice. A comprehensive analysis of regional brain extracts from these bigenic mice at a presymptomatic age reveals normal levels of total and abnormally phosphorylated (AT8, PHF1 and CP13) human tau irrespective of endogenous or pathogenic LRRK2 expression. Furthermore, we find no effect of LRRK2 on the solubility of human P301S-tau in buffers containing low salt, 1% Triton X100 or 1% sarkosyl. Importantly, we demonstrate for the first time that the expression of human G2019S-LRRK2 does not promote the phosphorylation or aggregation of human mutant tau throughout the mouse brain. Our data further demonstrate that endogenous LRRK2 does not play a prominent role in regulating the development or extent of tauopathy in the P301S-tau mice.
Our observations differ from a prior study suggesting evidence of increased tauopathy at 5.5 months of age in inducible forebrain-specific human P301L-tau transgenic mice (rTg4510 mice crossed with CamKIIa-tTA) when crossed with BAC transgenic mice expressing human WT LRRK2 (21). Bailey and colleagues report the accumulation and increased phosphorylation of tau at specific novel and known sites (pT149, pT205 and pS202/T205 [AT8]) in the sarkosyl-insoluble fraction from whole brain extracts (21) . Increased phosphorylated tau pathology (at pT149, pT153, CP13 and AT8 epitopes) was also reported in the cortex of these bigenic mice (21) . Our analysis of pS202 (CP13) and pS202/T205 (AT8) tau in multiple brain regions including the cortex did not reveal altered levels or pathology in bigenic mice compared with P301S-tau mice alone, and nor did we observe evidence of increased sarkosyl-insoluble tau in the bigenic mice. These differences could potentially relate to i) the age at which the P301S-tau mice were studied (and thus the extent of tauopathy versus the rTg4510 mice), ii) the effects of WT versus G2019S LRRK2 expression, iii) differences in the level and/or pattern of human LRRK2 transgene expression in our PDGFb-LRRK2 mice versus BAC-LRRK2 mice (i.e. cell type-specific or gene dosage effects), or iv) differences in human tau expression levels or patterns (i.e. PrP promoter-driven versus CamKIIa-specific). Our findings are similar to a recent study using the same P301S-tau transgenic mice as used herein crossed with BAC transgenic mice expressing human R1441G-LRRK2 (31) . The authors demonstrate similar levels of tau phosphorylation (at AT8, CP13 and PHF1 epitopes) in the bigenic mice compared with P301S-tau mice alone (31) . Furthermore, R1441G-LRRK2 expression did not exacerbate the onset of limb paralysis, premature survival or motoric deficits in the P301S-tau mice suggesting that pathogenic LRRK2 does not play an important role in the development or progression of tauopathy (31) . Our data similarly suggest that the most frequent G2019S mutation in LRRK2 also does not regulate tauopathy in the P301S-tau mice, whereas endogenous LRRK2 is also not required for the development of tau pathology in these mice.
Collectively, these observations demonstrate that endogenous or pathogenic LRRK2 plays a limited role in the neurodegenerative tauopathy that develops in P301S-tau mice, whereas the impact of LRRK2 in other tau mouse models is most likely to result from context-dependent effects (21, 22) . In our bigenic model, endogenous or pathogenic LRRK2 may not be prominently expressed in the same vulnerable neuronal populations that express P301S-tau (34) (35) (36) (37) . Although this scenario seems unlikely, it could provide one explanation for the lack of pathological interaction observed between LRRK2 and tau in this bigenic model. Accordingly, to address this potential issue, we developed a novel model of tauopathy based upon the delivery of AAV2/6 vectors expressing human P301S-tau to a known vulnerable neuronal population that also expresses endogenous or pathogenic LRRK2 (35) (36) (37) . We found that P301S-tau expression specifically induces phosphorylated tau pathology (AT8, CP13, PHF1 and MC1 epitopes) and neuronal loss localized to neurons of the CA1 region of the ipsilateral hippocampus, whereas tau pathology also develops in interconnected regions including the ipsilateral CA3 region and adjacent cortical areas. Similar to our studies of bigenic mice, we found that tau pathology and neurodegeneration in this AAV-based model of tauopathy occur largely independently from endogenous or pathogenic LRRK2 expression. Collectively, these data convincingly suggest that endogenous LRRK2 is not required for P301S-tau-induced pathology and neurodegeneration, and that G2019S LRRK2 does not promote the development or progression of tauopathy in this model. We noticed that P301S-tau expression was able to spread from the site of AAV vector delivery in the CA1 region to interconnected structures either due to viral infection, neuron-toneuron transfer of tau, or a combination of both. This prompted us to develop new AAV vectors that co-express human WT-tau and GFP from the same PGK1 promoter, to further explore the neuron-to-neuron transmission of tau within the hippocampus. The neuron-to-neuron transmission of tau is considered to play an important role in the development and progression of taupositive neuropathology in human tauopathies such as Alzheimer's disease (40, (42) (43) (44) . In contrast to P301S-tau, we found that WT-tau exhibits enhanced spread throughout the hippocampus including to the contralateral hemisphere but fails to induce prominent tau pathology or neuronal loss. These features make it ideal for monitoring neuronal tau transmission (versus viral infection) without the potentially confounding effects of tau pathology and neuronal damage. Importantly, we provide evidence that WT-tau undergoes neuron-to-neuron transmission in the hippocampus from ipsilateral CA1 neurons to both ipsilateral CA3 and contralateral CA3 neurons via the commissural fiber pathway that connects both hemispheres. We demonstrate for the first time that endogenous LRRK2 is not required for the neuronal transmission of WT-tau, however, we find that G2019S-LRRK2 can markedly enhance neuronal tau transmission. The mechanism underlying this enhanced WTtau transmission by G2019S-LRRK2 is unclear but could conceivably involve elevated kinase activity, a known property of this pathogenic mutation (45, 46) . Since WT-tau does not induce prominent pathology in this AAV-based model (compared with P301S-tau), the enhanced neuronal transmission induced by G2019S-LRRK2 does not obviously promote tau aggregation or neuronal loss within the timeframe evaluated. It is plausible that over a prolonged period the enhanced neuronal spreading of WT-tau could manifest as neuropathology. One potential caveat of our approach is that it is not possible to distinguish between the pathogenic effects of the G2019S mutation versus human LRRK2 overexpression in general in driving the increased WT-tau transmission. Since altering endogenous LRRK2 expression levels (WT versus KO mice) does not influence WT-tau neuronal transfer, this would tend to support a specific effect of the G2019S mutation in promoting tau transmission. It will be important in future studies to address whether the capacity to enhance tau transmission is shared by other pathogenic mutations in LRRK2, such as R1441C or Y1699C, and whether pharmacological kinase inhibition of G2019S-LRRK2 can attenuate the enhanced neuron-to-neuron transfer of tau. Mechanistically, it is unclear how G2019S-LRRK2 promotes the neuronal transmission of tau in this model. This could conceivably arise through the direct phosphorylation of tau by LRRK2 in vivo at T149, T153 or T181 (21, 24) , although our in vitro kinase assays suggest that LRRK2 is not able to robustly phosphorylate tau (compared with itself or ArfGAP1) and nor do we observe an interaction of LRRK2 and tau in human cells. Alternatively, this might be mediated by the indirect phosphorylation of tau by another kinase, such as GSK3b or cdk5 (22, 25, 26) , or could result from an impaired association of tau with the microtubule network (23, 47) . LRRK2 is known to robustly interact with b-tubulin isoforms whereas pathogenic LRRK2 mutants have been shown to disrupt microtubule networks (23, (47) (48) (49) .
In summary, we have employed two distinct mouse models of tauopathy as well as in vitro assays and cellular models to comprehensively explore the pathological interaction of LRRK2 and tau in mediating neurodegeneration. Our data demonstrate that endogenous or pathogenic LRRK2 expression does not play a major role in regulating human P301S-tau-induced neuropathology or neurodegeneration in the mouse brain, although we identify a novel role for G2019S-LRRK2 (but not endogenous LRRK2) in promoting the neuron-to-neuron transmission of WT-tau. These findings may have important implications for understanding the development of tau neuropathology in certain LRRK2 transgenic mice and some cases of LRRK2-linked PD.
Materials and Methods
Animals
All animal experiments were approved by the SCAV (Service de la consummation et des affaires vété rinaires) in the Canton de Vaud, Switzerland (Animal authorization No. 2572), and conducted in strict accordance with the European Union directive (2010/63/EU) for the care and use of laboratory animals. Animals were maintained in a pathogen-free barrier facility and exposed to a 12 h light/dark cycle with food and water provided ad libitum.
Generation of double mutant mice
Transgenic mice expressing human P301S-Tau (4R1N isoform) under the control of the mouse prion protein (PrP) promoter (line PS19; Jackson Labs, stock #008169) were described previously (34) and have been maintained on a C57BL/6J background. LRRK2 KO mice with a deletion of exon 40-41 were reported previously (33) , and subsequently maintained on a C57BL/6J background. Transgenic mice expressing human G2019S-LRRK2 under the control of a hybrid CMV-enhanced human PDGFb promoter (line 340; Jackson Labs, stock #016575) were reported previously (35) and maintained on a C57BL/6J background. Double mutant mice expressing human P301S-Tau in the absence of LRRK2 (P301S-Tau/LRRK2-KO) and appropriate littermate controls were generated in two successive crossbreeding steps as described previously (32) . Briefly, homozygous LRRK2-KO mice were crossed with hemizygous P301S-Tau mice to generate double mutant mice (P301S-Tau/LRRK2 þ/À ). These progeny were crossed with heterozygous LRRK2 þ/À mice to produce all four genotypes for analysis. Bigenic mice were generated by crossing hemizygous P301S-Tau and G2019S-LRRK2 transgenic mice in a single crossbreeding step. Mice were identified by genomic PCR with specific primer pairs: G2019S-LRRK2 transgenic mice (CMVe-F1, 5'-ATTACCATGGTTCGAGGTGA-3' and CMVe-R1, 5'-CAAGTGTCTGCAGGAAGGTT-3' producing a 170 bp transgene fragment), PrP-P301S-Tau mice (12473 forward, 5'-GGTATT AGCCTATGGGGGACAC-3' and 16134 reverse, 5'-GGCATCT CAGCAATGTCTCC-3' producing a 450 bp transgene fragment) and LRRK2-KO mice (LRRK2geno.for, 5'-GTGTTAAAGCTCCAG TTGCCT-3', LRRK2geno.rev2, 5'-GGGAAAGCATTTAGTCTGACC-3' and LRRK2_Ex41.rev, 5'-CAGTACTGTGCGATCCCGTA-3', producing 700 and 371 bp fragments from the WT allele, and a 253 bp fragment from KO allele).
Adeno-associated viral vectors (AAV2/6)
Plasmids coding for AAV2 vectors expressing human P301S-tau (4R0N isoform) were generated by cloning a full-length human P301S-tau (4R0N isoform) cDNA into a pAAV-PGK1-MCS-WPRE plasmid under the control of a PGK1 promoter. The generation of an empty AAV-PGK-MCS-WPRE vector has been described previously (50) . A bicistronic AAV2 vector was generated by cloning full-length human WT-tau (4R0N isoform) cDNA into the multiple cloning site of an expression cassette driven by the human PGK1 promoter. This bicistronic AAV vector used for eGFP nls /Tau overexpression is derived from the bicistronic lentiviral vector originally generated by Amendola et al. (51) . Bidirectional expression of both transgenes is driven by the human PGK1 promoter. In the opposite direction, the PGK1 promoter is combined with a minimal CMV promoter for expression of eGFP fused with a C-terminal nuclear localization signal (eGFP nls ). A vector map for the AAV-tau-WT/eGFP construct described above is depicted in Supplementary Material, Figure  S7 . The production of recombinant AAV2/6 vectors and the measurement of virus infectivity was performed as previously described (52) . The titers measured for AAV-PGK-MCS-WPRE, AAV-PGK-tau-P301S-WPRE and AAV-PGK-tau-WT/eGFP vectors were 2.5 x 10 10 , 1.9 x 10 10 and 2.0 x 10 10 TU/ml, respectively.
Brain tissue sequential fractionation
Brain tissues from LRRK2/tau mice for biochemical analyses were harvested at $24 weeks of age (n ¼ 4 mice/genotype). Brains were dissected into six distinct regions (cortex, striatum, ventral midbrain, brainstem, cerebellum and spinal cord). To analyse tau protein solubility and phosphorylation, brain tissues were subjected to sarkosyl sequential fractionation as described previously (53) . Specifically, brain tissues were first homogenized in 5 volumes of low-salt lysis buffer ( Supernatants from this second extraction were saved as the Triton-X100-soluble fraction. One third of the volume of the Triton-X100-soluble fraction was processed for sarkosyl extraction by adding 1% sarkosyl (Sigma) and incubation at 37 C with shaking for 1 h before centrifugation at 180,000g for 30 min at room temperature. Supernatants were saved as the sarkosylsoluble fraction. Final pellets were resuspended in 2X Laemmli buffer and saved as the sarkosyl-insoluble fraction. For each fraction, total protein concentration was determined by BCA assay (Pierce Biotech).
Western blot analysis
For analysis of tau species, equivalent protein samples were mixed in a 1: 1 ratio with 2X Laemmli sample buffer and denatured at 95 C for 5 min. Protein samples were resolved by SDS-PAGE using 7.5% Tris-Glycine gels followed by electrophoretic transfer onto nitrocellulose membranes (0. 
Stereotactic surgery
Female and male adult littermate mice aged from 20 to 28 weeks were subjected to stereotactic surgery for the unilateral delivery of AAV2/6-PGK1-Tau-P301S, AAV2/6-PGK1-MCS-WPRE or AAV2/6-PGK1-Tau-WT/eGFP vectors. Animals were deeply anesthetized by intraperitoneal injection of xylazine (10 mg/kg) and ketamine (100 mg/kg), placed into a stereotactic frame (Model 963-A, David Kopf Instruments) and an incision was made in the scalp. To deliver AAV vectors to the hippocampal CA1 region, the following coordinates were used: (anterior-posterior, À2 mm from bregma line, mediolateral, þ1.5 mm relative to bregma, dorsoventral, À1.5 mm relative to the skull). 1 ml of viral vector (containing $1 x 10 7 TUs) was injected per site at a rate of 0.2 ll/min with an automatic pump (CMA Microdialysis) and the needle was left in place for an additional 5 min before being slowly withdrawn to allow the tissue to close over and minimize leakage of the injected fluid. The skin was sterile sutured and the animals were monitored until they recovered from anesthesia. The animals were euthanized for perfusionfixation at 8 weeks post-surgery.
Tissue processing and immunohistochemistry
At 8 weeks post-injection, mice were anesthetized with pentobarbital and perfused transcardially with saline followed by 4% paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.3). After post-fixation for 90 min in 4% PFA and cryoprotection in 30% sucrose solution the brains were dissected into 40 lm-thick coronal sections using a sliding microtome (SM2010R, Leica). For chromogenic immunostaining, sections were washed three times in TBS then blocked for endogenous peroxidase activity by incubation in 3% H 2 O 2 (Sigma) diluted in methanol for 10 min at 4 C. Sections were blocked for non-specific binding in TBS containing 10% of goat serum (Invitrogen) supplemented with 0.1% Triton-X100 for 1 h at room temperature. Sections were incubated in primary antibodies for 48 h at 4 C and biotinylated secondary antibodies (Vector Labs) for 2 h at room temperature. After incubation with ABC reagent (Vector Labs) for 1 h at room temperature and visualization in 3, 3'-diaminobenzidine tetrahydrochloride (DAB; Vector Labs), sections were mounted on Superfrost plus slides (Fisher Scientific), dehydrated with increasing ethanol concentrations and xylene, and coverslipped using Entellan (Merck). Images were captured using a light microscope (Axio Imager M2, Zeiss) equipped with a color CCD camera (AxioCam, Zeiss). For fluorescence immunostaining, sections were washed three times in TBS then blocked for non-specific binding in TBS containing 10% of goat serum (Invitrogen) supplemented with 0.1% Triton-X100 for 1 h at room temperature. Sections were incubated in primary antibodies for 48 h at 4 C and secondary antibodies conjugated to AlexaFluor-488 or AlexaFluor-594 (Life Technologies) for 2 h at room temperature. Sections were washed in TBS þ 0.1% Tween 20 and mounted on Superfrost plus slides (Fisher Scientific) and coverslipped using Prolong mounting medium containing DAPI (Invitrogen). Sections were imaged using epifluorescent Leica DM5500B or NikonA1 plus confocal microscopes.
Stereological analysis
The total number of NeuN-positive neurons in the hippocampal CA1 region were quantified at 8 weeks post-injection (n ¼ 3-4 mice/group). Every 8 th serial section of 40 lm-thickness within this volume was examined. The unbiased stereological estimation of total neurons in the CA1 region was performed using the optical fractionator probe of StereoInvestigator software (MicroBrightField Biosciences). For the ipsilateral CA1 region, contours were traced around the lesion site as indicated in Figure 6 . Equivalent contours were traced in a symmetrical manner on the contralateral CA1. Sampling was performed in a systematic random manner using a grid of 50 x 50 lm squares and applying an optical dissector consisting of a 30 Â 30 Â16 lm square cuboid. All analyses were performed in a blinded manner.
Expression plasmids
Mammalian expression plasmids containing codon-optimized FLAG-tagged full-length human LRRK2 (WT, R1441C, Y1699C and G2019S) have been described previously (39, 54) . Myc-tagged human tau (4R0N isoform; WT and P301L variants) plasmids (55) were kindly provided by Dr. Leonard Petrucelli (Mayo Clinic Jacksonville, Florida).
Cell culture and transient transfection
HEK-293T cells were maintained in Dulbecco's modified Eagle's media supplemented with 10% fetal bovine serum and 1x penicillin/streptomycin at 37 C in a humidified atmosphere containing 5% CO 2 . Cells were transfected with plasmid DNAs using X-tremeGENE HP DNA Transfection Reagent (Roche Applied Science). Cells were routinely harvested at 48 h posttransfection for biochemical assays.
Co-immunoprecipitation (co-IP) assay
Co-IP assays were conducted as previously described (39, 56 Protein G-Dynabeads (Invitrogen) pre-coupled with mouse anti-FLAG-M2 (5 lg; Sigma) or mouse anti-myc (5 lg, clone 9E10; Roche Applied Science) antibodies. Dynabead complexes were washed five times with 1 ml IP buffer and proteins were eluted at 70 C for 10 min in Laemmli sample buffer (Bio-Rad) containing 5% 2-mercaptoethanol. IPs and input lysates (1% total) were resolved by SDS-PAGE, transferred to nitrocellulose (0.2 lm; Amersham), and subjected to Western blotting with appropriate primary and secondary antibodies.
In vitro kinase assay The reaction mixtures were terminated by adding 5 ml of 4x LDS sample buffer (Invitrogen) followed by denaturing the samples at 70 C for 10 min. As a control, we incubated Tau or LRRK2 alone with all other reaction components and as a positive control, we used recombinant GST-tagged rat ArfGAP1. Samples were resolved on 4-12% Bis-tris SDS-PAGE gels (Invitrogen), transferred onto PVDF membranes (GE Life Sciences) and subjected to autoradiographic detection using a Phosphor-imager. Membranes were then blocked with TBS þ 0.1% Tween20 containing 5% milk and incubated with anti-GST-HRP antibody (GE Life Sciences) and mouse anti-tau antibody (HT7; Millipore). Proteins were visualized using enhanced chemiluminescence (GE Life Sciences) and a luminescent image analyzer (LAS-3000, Fujifilm).
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